Log In
Print this Print this

NovoNorm, Prandin, Surepost, repaglinide (SMP-508)

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionShort-acting beta cell stimulating meglitinide
Molecular Target ATP-dependent potassium channel (KATP)
Mechanism of ActionATP-dependent potassium channel (KATP) blocker
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
PartnerShionogi & Co. Ltd.;
Sumitomo Dainippon Pharma Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today